Royalty Pharma to Present at Upcoming Investor Conferences

Rhea-AI Summary

Royalty Pharma plc (Nasdaq: RPRX) announced its participation in two investor conferences in September 2021. The events include Citi’s 16th Annual BioPharma Virtual Conference on September 9 at 10:40 a.m. EDT and Morgan Stanley’s 19th Annual Global Healthcare Conference on September 14 at 11:00 a.m. EDT. Webcasts will be available on Royalty Pharma’s 'Events' page and archived for at least 30 days. Royalty Pharma is known for acquiring biopharmaceutical royalties and funding innovation in the industry, with royalties on over 45 commercial products.

NEW YORK, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September:

• Citi’s 16th Annual BioPharma Virtual Conference on Thursday, September 9 at 10:40 a.m. EDT
• Morgan Stanley’s 19th Annual Global Healthcare Conference on Tuesday, September 14 at 11:00 a.m. EDT

The webcasts will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. Webcasts will also be archived for a minimum of thirty days.

About Royalty Pharma plc

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small- and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 45 commercial products, including AbbVie and Johnson & Johnson’s Imbruvica, Astellas’ and Pfizer’s Xtandi, Biogen’s Tysabri, Johnson & Johnson’s Tremfya, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and nine development-stage product candidates. For more information, visit www.royaltypharma.com.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772
ir@royaltypharma.com

FAQ

What investor conferences will Royalty Pharma (RPRX) participate in September 2021?

Royalty Pharma will participate in Citi’s 16th Annual BioPharma Virtual Conference on September 9 and Morgan Stanley’s 19th Annual Global Healthcare Conference on September 14, 2021.

What time will Royalty Pharma's presentations occur at the September investor conferences?

Royalty Pharma's presentation at Citi’s conference is scheduled for September 9 at 10:40 a.m. EDT, and at Morgan Stanley’s conference on September 14 at 11:00 a.m. EDT.

Where can I watch the webcasts of Royalty Pharma's investor presentations?

The webcasts will be accessible from Royalty Pharma’s 'Events' page on their website and will be archived for a minimum of thirty days.

What is Royalty Pharma's stock symbol?

Royalty Pharma's stock symbol is RPRX.

How does Royalty Pharma contribute to the biopharmaceutical industry?

Royalty Pharma funds innovation by acquiring biopharmaceutical royalties and partnering to co-fund late-stage clinical trials and new product launches.